Objective Shewanella bacteremia is an uncommon but potentially fatal disease. Although hepatobiliary diseases have been proposed to be risk factors for various Shewanella infections, little is known about the features of Shewanella bacteremia in patients with hepatobiliary diseases. This study aims to characterize the presentation and risk factors of Shewanella bacteremia in patients with hepatobiliary diseases. Methods We retrospectively investigated the clinical features, microbiology and outcomes of patients with Shewanella bacteremia who were admitted to a tertiary medical center between January 2001 and December 2010. All isolates were confirmed to the species level using 16S rRNA sequencing analyses. The English language medical literature was searched for previously published reports. Results Fifty-nine cases of Shewanella bacteremia, including nine at the hospital, were identified, 28 (47.4%) of which involved underlying hepatobiliary diseases, representing an important risk factor. In 12 of the 28 cases, the infections involved the hepatobiliary system; with a tendency towards an Asian origin. In our case series of nine patients, Shewanella haliotis was isolated in five patients. The majority of our patients lived in coastal areas, consumed seafood regularly and developed bacteremia during the summer season. Conclusion It is recommended that the possibility for Shewanella infection be considered in patients with bacteremia and also underlying hepatobiliary diseases, particularly if patients present with hepatobiliary infections, a history of seafood, or development of the disease during the summer.
Introduction
Shewanella is a non-fermentative Gram-negative bacilli found in aquatic environments throughout the world. Bacteremia caused by Shewanella is an uncommon but potentially fatal disease. The mortality rate of Shewanella bacteremia is 28% (1) . However, the mortality may rise to more than 50% in patients with underlying hepatobiliary diseases (2) . Moreover, despite the administration of aggressive critical care and antimicrobial therapy, rapid fatal cases are still reported (3) .
The genus Shewanella includes 59 recognized species at the time of this writing (http://www.bacterio.cict.fr/s/ shewanella.html). Most reported human infections are caused by Shewanella algae and Shewanella putrefaciens. However, it is often difficult to identify the microbes at the species level using conventional microbiologic culture and biochemical analyses. In addition, many automated identification systems include only S. putrefaciens in their database.
DNA sequencing provides an opportunity for definitive identification (4) . By incorporating 16S rRNA gene sequencing into the identification of Shewanella, more Shewanella species can be recognized as pathogenic organisms (5) (6) (7) .
Shewanella is primarily an opportunistic pathogen that causes three patterns of infection: soft tissue infection, bacteremia and neonatal sepsis (3) . In the majority of cases, the organism is cultured from and related to soft tissue infections, primarily in patients with associated underlying illnesses. Sea water exposure is a common environmental factor linked with soft tissue infections. Recently, the number of case reports of severe Shewanella bacteremia has increased. Many of these patients were reported to have underlying hepatobiliary diseases and were from Asian regions (3, 8, 9) . Previous analyses also suggest that hepatobiliary diseases are a risk factor for the development of various Shewanella infections; however, little is known about the roles of predisposing factors in bacteremia. The predisposing factors, clinical presentation, treatments and outcomes of Shewanella infection are poorly characterized.
We therefore conducted a 10-year retrospective study to review cases of Shewanella bacteremia occurring at our institution. The aim of this study was to investigate the clinical and microbiologic characteristics of Shewanella bacteremia, especially in patients with hepatobiliary diseases. All isolates were confirmed to the species level using 16S rRNA sequencing analyses. The susceptibility of the Shewanella isolates to various antibiotics was determined. In this report, we also review similar cases reported elsewhere in order to summarize the important features of this disease.
Materials and Methods
This retrospective study was conducted at Taichung Veterans General Hospital, a tertiary medical center in central Taiwan. All patients included were diagnosed with Shewanella bacteremia between January 2001 and December 2010. The patients were identified using the computerized database of the institution. Clinical, laboratory and microbiologic data were retrieved from the medical records of the patients. A standardized case record form was used by two experienced physicians to record the demographic profile, underlying condition, clinical presentation, therapy and outcome of each patient.
All isolates from patients with Shewanella bacteremia were re-identified using Gram staining, colony morphology and biochemical characteristics (10) . The organisms were further confirmed with 16S rRNA gene sequence analysis (11) (12) (13) . The primers used for amplification of the 16S rRNA gene were B27F (5'-AGAGTTTGATCCTGGCTCAG-3') and U1492R (5'-GGTTACCTTGTTACGACTT-3'). The amplification products obtained with polymerase chain reaction (PCR) were sequenced, and the sequences were compared to known 16S rRNA gene sequences in the GenBank database of the National Center for Biotechnology Information using the Basic Local Alignment Search Tool (BLAST) algorithm. The closest matches and GenBank accession numbers were obtained.
The minimum inhibitory concentrations (MICs) for ampicillin/sulbactam, piperacillin, piperacillin/tazobactam, cefazolin, cefoxitin, ceftazidime, ceftriaxone, cefepime, ciprofloxacin, imipenem, gentamicin, and trimethoprimsulfamethoxazole were determined using the VITEK II automated system (bioMérieux, France). Next, the disk-diffusion method was used as a confirmatory tool. There are no recognized Clinical and Laboratory Standards Institute (CLSI) MIC interpretive standards specified for this bacterial genus, and the MIC breakpoints of cefazolin, cefoxitin and ampicillin/sulbactam for non-fermentative Gram-negative bacilli are also lacking in the CLSI database. In the present report, the MIC breakpoints of piperacillin (susceptible, ! 16 μg/mL; intermediate, 32- μg/mL) and trimethoprim-sulfamethoxazole (susceptible, ! 2/ 38 μg/mL; resistant, " 4/76 μg/mL) were interpreted using CLSI approved standard M100-S22 categories for other nonEnterobacteriaceae in accordance with previous reports (7, 9, 14) . In addition, the standards recommended by the U.S. Food and Drug Administration (FDA) for ampicillin/sulbactam (susceptible, ! 8 μg/mL; intermediate, 16 μg/ mL; resistant, " 32 μg/mL), cefazolin (susceptible, ! 16 μg/ mL; resistant, " 64 μg/mL) and cefoxitin (susceptible, ! 8 μg/ mL; intermediate, 16 μg/mL; resistant, " 32 μg/mL) were used.
Previously published cases of Shewanella bacteremia in adults were reviewed. The English language medical literature was searched using the online bibliographic database of the National Library of Medicine (MEDLINE, PubMed). The search terms included "Pseudomonas putrefaciens," "Shewanella," "Shewanella putrefaciens," "Shewanella alga," "Shewanella algae," "bacteremia" and "bloodstream infection." All studies identified were reviewed, as were the references cited in the articles found in the original search.
Fisher's exact test was used to compare categorical variables. Continuous variables were compared using the Wilcoxon rank-sum test, as appropriate. p<0.05 was considered statistically significant. All statistical analyses were performed using the SPSS, version 15.0 software program (SPSS, Chicago, IL). 
Results
Nine patients with Shewanella bacteremia were identified during the study period ( Table 1 ). The patients included eight men and one woman, with ages ranging from 47 to 91 years (median age: 71 years). Eight of the nine patients had underlying hepatobiliary diseases, including liver cirrhosis, hepatitis, biliary tract stones or hepatobiliary malignancies. Shewanella bacteremia was the initial presentation of hepatobiliary malignancy in four of the five patients with cancer, including patients with cholangiocarcinoma, ampullary carcinoma and hepatoma. Seven patients had splenomegaly at the time of bacteremia onset. Five patients had underlying cardiovascular lesions, including two patients with aortic dissection, two patients with aortic insufficiency and one patient with deep vein thrombosis. Five patients had hypochlorhydria, either because they had previously undergone gastrectomy or because they were receiving either proton pump inhibitors or H2-receptor antagonists.
Shewanella bacteremia was associated with hepatobiliary infections in six patients, including patients with cholangitis, cholecystitis, liver abscesses or infected bilomas. In two patients, no evident sites of infection were established. The infected focus was cellulitis in one patient. Most patients did not undergo any medical procedures before developing bacteremia; however, in one patient, the bacteremia followed a liver biopsy. No patients were receiving antibiotics or corticosteroids at the time of development of bacteremia.
In the nine patients, the causative Shewanella species were Shewanella haliotis (in five patients [55.5%]), S. algae (in three patients [33.3%] ) and S. putrefaciens (in one patient [11.1%] ). The majority of patients had monomicrobial bacteremia. Three patients had polymicrobial bacteremia, and the concomitant pathogens included E. coli (in two patients), Klebsiella pneumoniae (in one patient), and Acinetobacter baumannii (in one patient).
A comparison of the clinical features of patients with S. haliotis bacteremia and those with non-S. haliotis bacteremia is shown in Table 2 . We did not find any statistically significant differences in any values between the five cases of S. haliotis and the four cases of other Shewanella species, although more patients in the S. haliotis bacteremia group presented with systemic symptoms, such as fever, chills and shock. These patients also had higher WBC counts and hepatic dysfunction of greater severity than did the patients with non-S. haliotis bacteremia.
Seven of the nine patients developed Shewanella bacteremia between July and September, with a peak number (five patients) developing the disease in September. Six of the nine patients lived in coastal areas. Two of the other three patients consumed seafood regularly. Figure shows the mean sea surface temperature and the number of cases of Shewanella bacteremia.
Concerning antibiotic therapy, most of the patients received broad-spectrum β-lactam antibiotics, including amoxicillin-clavulanate (three patients), cefmetazole (two patients), cefoxitin (one patient), flomoxef (one patient), cefpirome (one patient) and ampicillin (one patient). Two patients died due to severe sepsis.
The MICs of the clinical isolates of the 12 antimicrobial agents are listed in Table 3 . All tested Shewanella isolates were found to be susceptible to piperacillin, piperacillintazobactam, ceftriaxone, cefepime, ciprofloxacin, imipenem, gentamicin and trimethoprim/sulfamethoxazole. Of the tested isolates, 88.8% were susceptible to ampicillin-sulbactam and ceftazidime and 66.63% were susceptible to cefoxitin. The majority of tested Shewanella isolates were resistant to cefazolin (77.7%).
Our search of the Medline database revealed 28 articles concerning Shewanella bacteremia in adults. Clinical details were available for 50 cases (1-3, 6, 8, 9, 14-35), 20 (40%) of which involved underlying hepatobiliary diseases (Table 4). Of these 20 patients, 15 (75%) were men, and the Sea surface temperature C median age was 64.5 years (range: 42 to 85 years). Fifteen of the 20 patients were 60 years of age or older. The majority of patients presented with hepatobiliary infections (six cases, 30%), primary bacteremia (six cases, 30%) and soft tissue infections (five cases, 25%). The underlying hepatobiliary diseases included liver cirrhosis, hepatitis, biliary tract stones and hepatobiliary malignancies. Sixteen of the 20 patients (80%) lived in Asian regions, including Japan, Korea, Hong Kong and Taiwan.
Ten patients had monomicrobial infections. In cases of polymicrobial infection, the co-isolates included E. coli (six cases), Enterococcus species (one case), Klebsiella species (two cases), Aeromonas species (two cases), Morganella morganii (one case), Serratia marcescens (one case), Flavobacterium odoratium (one case), Edwardsiella tarda (one case) and Citrobacter diversus (one case).
In total, there were 28 patients with underlying hepatobiliary diseases who developed Shewanella bacteremia. Among these patients, eight patients (28%) died, at an average age of 67.7 years. The underlying liver disorder was malignancy in five of the eight fatal cases. All fatal cases involved sepsis, and four fatal cases involved polymicrobial bacteremia. Blood cell counts were available in five of the eight fatal cases. All of these five patients had peripheral blood cytopenias, including neutropenia in three cases, anemia in three cases and thrombocytopenia in five cases. Two patients developed concomitant renal failure.
Discussion
This study reported nine cases of Shewanella bacteremia, including the first reported cases of S. haliotis bacteremia. Together, our data and the literature review show that of 59 bacteremic patients, 28 (47.4%) had underlying hepatobiliary diseases, representing an important risk factor. Hepatobiliary infections were present in a total of 12 (42.8%) of 28 patients with underlying hepatobiliary diseases with a tendency toward an Asian origin. In our case series, six (66.6%) of the patients lived in coastal areas and seven (77.7%) developed Shewanella bacteremia during the summer. The Shewanella isolates evaluated in this study were found to be susceptible to most third-and fourth-generation cephalosporins and piperacillin/tazobactam and resistant to cefazolin.
Our results indicate that hepatobiliary diseases, reported in 88.8% of the patients in our series, represent an important risk factor in patients with Shewanella bacteremia. These findings are consistent with those of previous Asian studies (9, 27). In a case series conducted in Hong Kong, 50% 
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S. haliotis of patients with Shewanella bacteremia had hepatobiliary diseases (9) . An earlier report of Shewanella soft tissue infection in Taiwan also showed hepatobiliary disease to be a major risk factor among patients with bacteremic complications (27) . Our study showed a strong association between Shewanella infection and hepatobiliary malignancies. Moreover, most of the patients in this study were newly diagnosed with hepatobiliary malignancies, and Shewanella bacteremia was the initial presentation in most cases. In addition, the majority of our patients presented with hepatobiliary infections. Ascending infections facilitated by abnormal hepatobiliary anatomy may lead to the occasional development of hepatobiliary infections caused by Shewanella. The organism has been isolated from bile since it was first described as a possible human pathogen in 1970 (36) and is known to be associated with various hepatobiliary infections, including cholecystitis, cholangitis and liver abscesses (1, 17, 37). Many of the reported patients had under-lying hepatobiliary structural abnormalities. The lipophilicity of Shewanella and its tolerance to bile salts are proposed causes of its affinity for bile and are possible virulence factors in the development of hepatobiliary infections (10, 27, 38) . Overall, in our series and literature review, 12 bacteremic patients presented with hepatobiliary infections, all of whom had underlying hepatobiliary diseases, particularly malignancies, that resulted in biliary tract obstruction. These findings demonstrate the importance of conducting appropriate imaging studies to determine the nature of any underlying abnormalities.
Patients with hepatobiliary diseases are also predisposed to other marine bacterial infections such as infection with Vibrio vulnificus or Aeromonas species. Iron overload is a known risk factor that is highly related to these situations due to its effects in decreasing neutrophil activity (39) . Similarly, Shewanella species are one of the most diverse respiratory organisms and have the ability to reduce iron (4). In addition, siderophores have been reported to be extracellular virulence factors of Shewanella species (10). Iron overload resulting from hepatic dysfunction has been speculated to be associated with Shewanella infection by some experts (9) . Associations with fulminant infections and associated splenic dysfunction have also been suggested (40) . A potential association with splenic dysfunction is supported by clear evidence of splenomegaly in our patients. Moreover, the majority of the fatal cases of Shewanella bacteremia in this study involved peripheral blood cytopenias, which are often attributed to functional overactivity of the spleen in patients with chronic liver disease (41) . Additional studies are therefore needed to further clarify this relationship.
Our findings also suggest an association between seafood consumption and the development of Shewanella bacteremia. The majority of our patients (8/9, 88.8%) lived in coastal areas and consumed seafood regularly. Furthermore, most patients (7/9; 77.7%) developed bacteremia during the summer season (July to September). Seawater contact is a risk factor for Shewanella soft tissue and ear infection (9, 42) . However, the route of transmission of bacteremia remains undetermined. Ingestion of seafood has been proposed as a possible explanation (9, 43) . There are case reports of Shewanella bacteremia following seafood intake (3, 8, 43) . Interestingly, the majority of cases are from Asian countries. Moreover, much of the literature that describes an association between Shewanella infection and hepatobiliary infection originates from Asian countries. These findings may be associated with contamination of seafood by Shewanella species, particularly in countries with a tradition of eating raw or undercooked seafood. Few studies have investigated the ability of Shewanella to colonize the gastrointestinal tract. However, there are reports of Shewanella being isolated from stool cultures. In reports from India, Shewanella was isolated from stool specimens of patients with diarrhea (44, 45) . In an 8-year study of Shewanella infection in Hong Kong (9), asymptomatic bile colonization was noted in five cases. In the same study, the intraabdominal region was the most common site of isolation.
The mean sea surface temperature of the central coastal area of Taiwan was found to be closely correlated with the number of cases of Shewanella bacteremia in our case series (Figure) . Shewanella is associated with aquatic environments and has been cultured from samples of animals that inhabit these ecosystems, including fish, mollusks and crustaceans (4) . Shewanella has also been cultured directly from samples of seawater (42) . Shewanella can grow over a wide range of temperatures, although it tends to be more common in warmer waters (4) . The mean sea surface temperature of the central coastal area of Taiwan rises from a low of 18.8 during the period from January to March to a high of 28.6 during the period from July to September. Seven of the nine patients in this study developed onset of illness during the warmer weather months of July, August and September. This association may reflect increased proliferation of Shewanella in warmer water, in seafood or both. In a study of Shewanella in Danish coastal water, the quantity of the organism was found to be correlated with the temperature of the seawater (42) . Seasonal variations in the amount of intestinal Shewanella in tilapia were also reported in a study from Saudi Arabia, a country at the same latitude as Taiwan (46) . Shewanella was the most abundant species of tilapia intestinal flora in that study, and the bacterial load was found to be highest in the summer. Adequate cooking kills Shewanella; however, seafood is often eaten raw or undercooked in countries like Japan, Taiwan and Korea, thereby increasing the risk of infection with Shewanella.
Our study suggests that S. haliotis may be a human pathogen within the Shewanella genus. S. haliotis was first detected in the gut of abalone in Korea (47) . Abalone is also a commercially important mollusk cultured on the coast of Taiwan. In the area where this study was conducted, it is a local custom for abalone to be eaten as a prized delicacy. Shewanella has also been isolated from abalone in the South China Sea (48) . The most commonly reported Shewanella species associated with human infections are S. algae and S. putrefaciens. However, the methods of species identification used in most reports include biochemical reactions or automated systems. These methods are not reliable for differentiating Shewanella species. Molecular typing required for definitive identification (4). 16S rRNA gene sequencing was crucial for identifying the Shewanella bacteremia presented in this study. The availability of this technology allowed us to recognize S. haliotis infections that otherwise would have been attributed to S. algae or S. putrefaciens. We recommend incorporating 16S rRNA gene sequencing into standard identification procedures for Shewanella infection. We believe this will result in improved identification of Shewanella species, as well as the ability to offer directed therapy and achieve improved clinical outcomes. In addition, this practice facilitates the identification of S. haliotis, suggesting that S. haliotis infections may be more common than previously recognized.
The antibiotic susceptibility patterns of our isolates are typical of those reported by others. Shewanella species are associated with the production of various β-lactamases, including chromosome-encoded class B and class D β-lactamases, while resistance to penicillin and first-generation cephalosporins are common (14, 49) . In addition, Shewanella has been noted to be less frequently susceptible to certain agents, including cefoxitin (1), and, more recently, imipenem (14) . Moreover, emergence of resistance to piperacillin-tazobactam (6) and imipenem (14) during treatment has been reported. These findings have particular significance when selecting antimicrobial agents for empirical treatment of biliary tract infections. Antibiotics such as cefazolin or cefoxitin, which are often administered to empirically treat intra-abdominal infections, may be ineffective if Shewanella species are present. Another area of concern is the presence of drug-resistant strains in the environment. The qnr gene has also been detected in Shewanella isolated from the coastal waters of China (50) . The plasmid-borne quinolone resistance gene is common in drug-resistant Enterobacteriaceae. Close monitoring for possible emergence of quinolone resistance in Shewanella is needed.
Our study is associated with some limitations. First, we reported detailed information from only one tertiary care center. In that sense, our data set does not represent patients overall and is subject to biases regarding referrals for advanced care. Patients with mild diseases were most likely underrepresented. Second, we were unable to obtain detailed information about the type, quantity and timing of seafood consumptions; thus, the incubation period cannot be determined. Third, while the major Shewanella species involved in human disease are known, whether other genomospecies can cause human infections remains uncertain. Also unknown is whether particular pathogenic groups are associated with specific clinical syndromes.
In conclusion, physicians should be aware of S. haliotis and related species in cases of bacteremia in patients with hepatobiliary diseases, particularly if patients present with hepatobiliary infections, a history of seafood consumption or development of the disease during the summer.
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